DermTech, Inc. (DMTKQ) vs ProPhase Labs, Inc. (PRPH)

DermTech, Inc. and ProPhase Labs, Inc. are both Diagnostics & Research companies. DermTech, Inc. is the larger, with a market value of $3.3M against $1.2M — 2.8× the size. DermTech, Inc. grew revenue faster over the last twelve months: 9.71% against −43.5%. DermTech, Inc. has the higher net margin (−572.2% vs −717.4%) and the lower return on invested capital (−5,493.5% vs −387.3%). Across the 16 metrics below, DermTech, Inc. leads on 8 and ProPhase Labs, Inc. on 8.

Valuation

Metric DMTKQ PRPH Diagnostics & Research median
P/E n/m n/m 33.95
P/S n/m 0.04 4.87
P/B n/m n/m 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA 0.45 n/m 25.20
EV/Sales (2.49) 1.84 5.66
Earnings yield 0.00% (23,896.00%) (1.75%)
Free cash flow yield 0.00% (3,945.49%) (0.13%)

Profitability

Metric DMTKQ PRPH Diagnostics & Research median
Gross margin 8.51% 16.38% 50.89%
Operating margin (588.62%) (498.73%) (8.57%)
Net margin (572.19%) (717.43%) (6.37%)
Free cash flow margin (460.10%) (175.22%) 0.00%
Return on equity (121.75%) (543.95%) (2.92%)
Return on assets (64.00%) (45.53%) (6.71%)
Return on invested capital (5,493.45%) (387.30%) 0.00%

Growth

Metric DMTKQ PRPH Diagnostics & Research median
Revenue growth (TTM) 9.71% (43.52%) 7.69%
EPS growth (last fiscal year) 20.36% 93.33% —
Revenue growth, 5-year CAGR 44.33% (21.43%) 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMTKQ PRPH Diagnostics & Research median
Debt to equity 0.00 (1.82) 0.11
Current ratio 3.53 0.05 2.02
Net debt to EBITDA 0.57 (0.74) 0.78

Dividend

Metric DMTKQ PRPH Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric DMTKQ PRPH Diagnostics & Research median
Market cap 3.29m 1.17m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack